Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Budesonide for maintenance of remission in eosinophilic esophagitis
NCT02493335Phase 3Completed
- Sponsor
- Dr. Falk Pharma GmbH
- Start
- Jan 2016
- Primary completion
- Nov 2018
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of EPI-EE in eosinophilic esophagitis (EoE) (3 arms), sponsored by Dr. Falk Pharma GmbH. Primary endpoint: Rate of patients free of treatment failure at 48 weeks. Started Jan 2016; status: completed.
02
Drugs
EPI-EE
03
Conditions
eosinophilic esophagitis (EoE)
Beyond the preview
Go deeper on NCT02493335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02493335.